Cynata Therapeutics Limited (CYP) Price & Analysis

Compare

9 Followers

CYP Stock Chart & Stats

AU$0.29

-AU$0.01(-4.17%)

At close: Jan 09 4:00 PM EST

AU$0.29

-AU$0.01(-4.17%)

Day’s Range― - ―

52-Week RangeAU$0.14 - AU$0.44

Previous CloseN/A

Volume63.41K

Average Volume (3M)233.82K

Market Cap

AU$78.36M

Enterprise ValueAU$74.50M

Total Cash (Recent Filing)AU$5.05M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta0.42

Next Earnings

Feb 19, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding237,454,380

10 Day Avg. Volume170,513

30 Day Avg. Volume233,823

Financial Highlights & Ratios

PEG Ratio0.21

Price to Book (P/B)5.14

Price to Sales (P/S)16.31

P/FCF Ratio-3.51

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetZero debt materially lowers solvency and interest burden risk for a clinical-stage biotech. This preserves flexibility to fund trials or pursue partnerships via equity or collaborations without fixed repayment stress, improving strategic optionality over the next 2–6 months.

Very High Gross MarginsNear-100% gross margins indicate highly scalable product economics for manufactured cell therapies once commercialized. Long-term, strong gross margins can support attractive royalty economics for partners and enable profitable unit economics as fixed R&D and SG&A are spread over higher volumes.

Platform-based Therapy ApproachA proprietary Cymerus iPSC-derived MSC platform is a durable competitive asset: it enables off-the-shelf manufacturing scalability, potential multi-indication application, and makes Cynata an attractive licensing or partnership target, supporting sustained business development opportunities.

Bears Say

Persistent Cash BurnConsistent negative operating and free cash flow forces reliance on external funding, increasing dilution and execution risk. Over a multi-quarter horizon this constrains clinical investment pacing and negotiating leverage with partners, making long-term program funding uncertain.

Declining Equity And Total AssetsMaterial declines in equity and assets reflect depletion of shareholder capital to fund operations. This reduces the balance sheet buffer against development setbacks, heightens the probability of further capital raises, and weakens financial resilience during lengthy clinical timelines.

Large Operating Losses & Negative MarginsSevere operating losses and deeply negative net margins (extreme in recent years) show the business is not near self-sustaining. Continued high cost base versus low, volatile revenue increases funding needs, complicates commercialization planning, and raises execution risk for long-term viability.

Cynata Therapeutics Limited News

Cynata to Host Investor Webinar and Expand Online Engagement With Shareholders

Cynata Therapeutics Limited ( ($AU:CYP) ) has provided an update. Cynata Therapeutics has scheduled an investor webinar for...

1d ago

Cynata Nears Key Data Readouts as Pivotal Cell Therapy Trials Advance

Cynata Therapeutics Limited ( ($AU:CYP) ) just unveiled an update. Cynata Therapeutics reported strong clinical and operational progress...

7d ago

Cynata Raises $1.2m via At-The-Market Facility to Support Cell Therapy Pipeline

An announcement from Cynata Therapeutics Limited ( ($AU:CYP) ) is now available. Cynata Therapeutics has raised approximately $1.2...

13d ago

Cynata Completes Enrollment in Phase 2 aGvHD Trial

The latest announcement is out from Cynata Therapeutics Limited ( ($AU:CYP) ). Cynata Therapeutics has completed patient enrollment...

2M ago

Cynata’s CYP-001 Therapy Shows Promise in Kidney Transplant Trial

Cynata Therapeutics Limited ( ($AU:CYP) ) has shared an announcement. Cynata Therapeutics announced a positive review by an...

2M ago

Cynata Therapeutics Updates Director’s Securities Holdings

Cynata Therapeutics Limited ( ($AU:CYP) ) just unveiled an announcement. Cynata Therapeutics Limited announced a change in the...

2M ago

Cynata Therapeutics Announces Change in Director’s Interest

Cynata Therapeutics Limited ( ($AU:CYP) ) has shared an announcement. Cynata Therapeutics Limited announced a change in the...

2M ago

Cynata Therapeutics Announces Change in Director’s Securities Interests

Cynata Therapeutics Limited ( ($AU:CYP) ) just unveiled an announcement. Cynata Therapeutics Limited announced a change in the...

2M ago

Cynata Completes Final Patient Visit in Phase 3 Osteoarthritis Trial

Cynata Therapeutics Limited ( ($AU:CYP) ) has issued an announcement. Cynata Therapeutics Limited announced the completion of the...

2M ago

Cynata Therapeutics Unveils Updated Investor Presentation

Cynata Therapeutics Limited ( ($AU:CYP) ) has shared an update. Cynata Therapeutics Limited has released an updated investor...

3M ago

CYP FAQ

What was Cynata Therapeutics Limited’s price range in the past 12 months?

Cynata Therapeutics Limited lowest share price was AU$0.14 and its highest was AU$0.43 in the past 12 months.

What is Cynata Therapeutics Limited’s market cap?

Cynata Therapeutics Limited’s market cap is AU$78.36M.

When is Cynata Therapeutics Limited’s upcoming earnings report date?

Cynata Therapeutics Limited’s upcoming earnings report date is Feb 19, 2026 which is in 14 days.

How were Cynata Therapeutics Limited’s earnings last quarter?

Cynata Therapeutics Limited released its earnings results on Aug 28, 2025. The company reported -AU$0.025 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.025.

Is Cynata Therapeutics Limited overvalued?

According to Wall Street analysts Cynata Therapeutics Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Cynata Therapeutics Limited pay dividends?

Cynata Therapeutics Limited does not currently pay dividends.

What is Cynata Therapeutics Limited’s EPS estimate?

Cynata Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cynata Therapeutics Limited have?

Cynata Therapeutics Limited has 237,454,380 shares outstanding.

What happened to Cynata Therapeutics Limited’s price movement after its last earnings report?

Cynata Therapeutics Limited reported an EPS of -AU$0.025 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.977%.

Which hedge fund is a major shareholder of Cynata Therapeutics Limited?

Currently, no hedge funds are holding shares in AU:CYP

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Cynata Therapeutics Limited Stock Smart Score

Neutral

Blogger Sentiment

Bullish

AU:CYP Sentiment 70%
Sector Average ―

Technicals

Fundamentals

Return on Equity

-138.54%

Trailing 12-Months

Asset Growth

-15.80%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cynata Therapeutics Limited

Cynata Therapeutics Limited (CYP) is an Australian biotechnology company focused on the development and commercialization of innovative stem cell therapies. The company specializes in Cymerus™, a proprietary technology for manufacturing mesenchymal stem cells (MSCs) at scale. This platform enables the production of therapeutic stem cells without the limitation of donor availability, supporting the treatment of various diseases and medical conditions. Cynata's core products target applications in regenerative medicine, encompassing indications such as cardiovascular disease, respiratory ailments, and graft-versus-host disease (GvHD).